ArticleSchizophrenia bulletin2026
Cortical Iron and Mesostriatal Dopamine Function in Schizophrenia: A Positron Emission Tomography and Magnetic Resonance Imaging Study.
Article in Schizophrenia bulletin, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
background and hypothesisElevated postmortem iron in Brodmann areas 10-11 has recently been linked to schizophrenia. Although in vivo studies have linked subcortical iron abnormalities to disease-related striatal hyperdopaminergia, in vivo cortical iron alterations have not been previously examined. We therefore used neuroimaging to test whether cortical iron is elevated in individuals with schizophrenia and whether this correlated with mesostriatal dopamine function. STUDY
designWe acquired quantitative susceptibility mapping magnetic resonance imaging (MRI) to measure magnetic susceptibility (χ), a marker of iron, in 149 participants aged 18-45 (73 with schizophrenia and 76 matched healthy controls). Subsets of patients with schizophrenia underwent [18F]-DOPA PET to estimate striatal dopamine synthesis capacity (n = 39) and neuromelanin-sensitive MRI of the dopaminergic midbrain (n = 68), as neuromelanin is a byproduct of dopamine synthesis. STUDY
resultsPrimary analyses showed no significant case-control differences in χ in the whole cortex (P = .675) or Brodmann areas 10-11 (P = .537). Exploratory analyses examined χ for 360 cortical regions, correcting for multiple comparisons. Two left temporo-parieto-occipital junction regions showed significantly elevated χ in schizophrenia: the posterior temporo-parieto-occipital junction the posterior temporo-parieto-occipital junction (d = 0.752, P < .001) and the superior temporal visual area (d = 0.638, P = .034). Mean χ across these regions inversely correlated with dopamine synthesis capacity in the associative (r = -0.37, P = .048) and limbic (r = -0.34, P = .048) striatum, and with neuromelanin-sensitive MRI values in the dopaminergic midbrain (r = -0.35, P = .005), corrected for multiple comparisons.
conclusionsThis study provides the first in vivo evidence of elevated cortical iron in schizophrenia and links this to mesostriatal dopamine dysfunction.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.